Healthcare Active Runners: Gilead Sciences (NASDAQ:GILD), Pfizer Inc. (NYSE:PFE), Merck & Co. (NYSE:MRK), MannKind Corporation (NASDAQ:MNKD)



Gilead Sciences, Inc. (NASDAQ:GILD) announced data from two Phase 2 studies and a compassionate access study in which a regimen containing once-daily Sovaldi(R) (sofosbuvir) 400 mg was administered for the treatment of chronic hepatitis C virus (HCV) infection in patients with advanced liver disease. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was -7.32% in last session and finished the day at $65.48. Traded volume was 43.15million shares in the last session and the average volume of the stock remained 14.39million shares. The beta of the stock remained 0.58. Gilead Sciences, Inc. (NASDAQ:GILD) insider ownership is 0.50%.

In 2004, Pfizer Inc. (NYSE:PFE), which purchased licensing rights for Depo Provera from Phramacia & Upjohn Inc., submitted information to the FDA stating that women who receive the Depo Provera injection experience significant loss of bone mineral density. The FDA responded by giving Depo Provera a “Black Box Warning” meaning all possible side effects would have to be discussed with any person receiving the drug. Pfizer Inc. (NYSE:PFE) dropped -1.99 percent to $30.61 Thursday on volume of 30.44million shares. The intra-day range of the stock was $30.51 to $31.43. Pfizer Inc. (NYSE:PFE) has a market capitalization of $195.71billion.

Merck & Co., Inc. (NYSE:MRK), known as MSD outside of the United States and Canada, today announced interim results from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of an all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection (GT1). Merck & Co., Inc. (NYSE:MRK)’s stock on Apr 10, 2014 reported a decrease of -2.19% to the closing price of $55.85. Its fifty two weeks range is $44.60 -$58.14. The total market capitalization recorded $164.23billion. The overall volume in the last trading session was 18.03million shares. In its share capital, MRK has 2.94billion outstanding shares.

MannKind Corporation (MNKD:NASDAQ), with its inhalable insulin product Afrezza (human insulin of recombinant DNA origin delivered via Technosphere particles). It had an AdCom meeting on April 1 and the PDUFA date is now set at July 15. On Thursday, shares of MannKind Corporation (NASDAQ:MNKD) dropped -2.14% to close the day at $6.85. Company monthly performance is recorded as 20.39%. MannKind Corporation (NASDAQ:MNKD) quarterly revenue growth is -3.25%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone